A woman in her 50s became the first patient to receive Amchepry, Japan's conditionally approved iPS-cell therapy for Parkinson's disease, at Kyoto University Hospital. Sumitomo Pharma says she is recovering well and has returned to work.
A vibrating wristband first built as a foamcore prototype in MIT's product-design class is now FDA-cleared for adults with essential tremor. In two trials, more than 70% of patients improved. Insurance coverage is the next hurdle.
Cerevance's experimental drug solengepras reduced the daily time people with Parkinson's spend with poorly controlled symptoms in a 341-person phase 3 trial, without adding troublesome involuntary movements.
Scientists sequenced mitochondrial DNA in individual brainstem neurons from people with Parkinson's for the first time, finding heavy damage but also a protective response that was stronger in people who lived longer.